

ICD-10-CM Expert for Physicians

The complete official guidelines and code set Codes valid from October 1, 2025 through September 30, 2026



Contents

	e ICD-10-CM Expert for Physicians 2026 iii	Chapter 12.	Diseases of the Skin and Subcutaneous Tissue (LØØ–L99)745
		Chapter 13.	Diseases of the Musculoskeletal System and
	ableiii	i i	Connective Tissue (MØØ–M99)767
	orrect Codingiii		Diseases of Genitourinary System (NØØ–N99)857
Official ICD-1	0-CM Guidelines for Coding and Reporting iii	Chapter 15.	Pregnancy, Childbirth, and the Puerperium (000–09A)879
Index to	Diseases and Injuriesiii	Chapter 16.	Certain Conditions Originating in the Perinatal Period (PØØ–P96)919
Table of	n Tableiii Drugs and Chemicalsiii	Chapter 17.	Congenital Malformations, Deformations, and Chromosomal Abnormalities (QØØ–Q99)933
Index No	Causes Indexiii tationsiv	Chapter 18.	Symptoms, Signs, and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified
Code and	of Diseasesv d Code Descriptionsv	Chapter 19.	(RØØ–R99)953 Injury, Poisoning, and Certain Other Consequences
	Notationsv V		of External Causes (SØØ–T88)975
	lotations vi		External Causes of Morbidity (VØØ–Y99)
	Vi	Chapter 21.	Factors Influencing Health Status and Contact with Health Services (Z00–Z99) 124
	rsvii	Chanter 22	Codes for Special Purposes (U00–U85)
Chapter-Leve	el Notations vii	Chapter 22.	Codes for Special Full poses (000-003)
Appendixes .	viii	Appendixe	esAppendixes–1
Illustrations	viji	Appendix A:	Valid 3-character ICD-10-CM CodesAppendixes-
		Appendix B:	Pharmacology List 2026Appendixes-3
	v for 2026ix tesix	Appendix C:	Z Codes for Long-Term Drug Use with
	lpdatesix		Associated Drugs Appendixes–18 Z Codes Only as Principal/
Conversion	n Table of ICD-10-CM Codesx	Appendix b.	First-Listed Diagnosis
			Centers for Medicare & Medicaid
10 Steps to	Correct Codingxii		Services Hierarchical Condition Categories (CMS-HCC)Appendixes-2
		A	-
	Official Guidelines for	Appendix F:	Centers for Medicare & Medicaid Services Quality Payment Program Appendixes – 2:
Coding and	d ReportingCoding Guidelines-1		services quanty raymener rogramman, appenances 20
ICD-10-CM	Index to Diseases and Injuries1	Illustration	ns Illustrations–1
		Chapter 3.	Diseases of the Blood and Blood-forming
ICD-10-CM	Neoplasm Table339		Organs and Certain Disorders Involving the Immune Mechanism (D50–D89)Illustrations—
ICD-10-CM	Table of Drugs and Chemicals358		Red Blood CellsIllustrations—
			White Blood CellIllustrations— PlateletIllustrations— Illustrations—
ICD-10-CM	Index to External Causes408		CoagulationIllustrations–2 Spleen Anatomical Location and
ICD-10-CM	Tabular List of Diseases and Injuries445		External Structures Illustrations—3
Chapter 1.	Certain Infectious and Parasitic Diseases (AØØ–B99), UØ7.1, UØ9.9445	Chapter 4.	Spleen Interior Structures Illustrations—3 Endocrine, Nutritional, and Metabolic
Chapter 2.	Neoplasms (C00–D49)	Спарсег 4.	Diseases (EØØ–E89) Illustrations–4
Chapter 3.	Diseases of the Blood and Blood-forming Organs		Endocrine System Illustrations—
	and Certain Disorders Involving the Immune		Thyroid Illustrations-5
Chapter 4.	Mechanism (D5Ø–D89)		Thyroid and Parathyroid Glands Illustrations—5 Pancreas Illustrations—6
Chapter 4.	(EØØ–E89)		Anatomy of the Adrenal Gland Illustrations—6
Chapter 5.	Mental, Behavioral, and Neurodevelopmental		Structure of an Ovary Illustrations—7
•	Disorders (FØ1–F99)553		Testis and Associated Structures Illustrations -
Chapter 6.	Diseases of the Nervous System (GØØ–G99)585	Charte	Thymus
Chapter 7.	Diseases of the Eye and Adnexa (HØØ–H59)609	Chapter 6.	Diseases of the Nervous System (GØØ–G99) Illustrations - S Brain Illustrations - S
Chapter 8.	Diseases of the Ear and Mastoid Process (H6Ø–H95) 645		Cranial NervesIllustrations—
Chapter 9.	Diseases of the Circulatory System (IØØ–I99)657		Peripheral Nervous System Illustrations – 10
Chapter 10.	Diseases of the Respiratory System (JØØ–J99), UØ7.Ø 703		Spinal Cord and Spinal Nerves Illustrations–17
Chapter 11.	Diseases of the Digestive System (KØØ–K95)719		Nerve CellIllustrations–12
			Trigeminal and Facial Nerve Branches Illustrations – 12

ICD-10-CM 2026 i

Contents ICD-10-CM 2026

Chapter 7.	Diseases of the Eye and Adnexa (HØØ–H59)	·	Diseases of the Skin and Subcutaneous Tissue (LØØ–L99)	Illustrations–31 Illustrations–32 Illustrations–32
Chapter 8.	Diseases of the Ear and Mastoid Process (H6Ø–H95)Illustrations–15 Ear AnatomyIllustrations–15		Shoulder Posterior View Elbow Anterior View Elbow Posterior View	Illustrations–33 Illustrations–33 Illustrations–33
Chapter 9.	Diseases of the Circulatory System (IØØ–I99)	Chapter 14.	Hand	Illustrations—34Illustrations—34Illustrations—34Illustrations—35Illustrations—35Illustrations—36Illustrations—37Illustrations—37Illustrations—37
Chapter 10.	Diseases of the Respiratory System (JØØ–J99), UØ7.Ø		Diamniotic (DI-DI) Twin Gestation—Monochorionic— Diamniotic (MO-DI) Twin Gestation—Monochorionic— Monoamniotic (MO-MO)	Illustrations–39
	Paranasal Sinuses	Chapter 19.	njury, Poisoning, and Certain Other Consequences of External Causes (SØØ–T88)	lllustrations–40
Chapter 11.	Diseases of the Digestive System (KØØ–K95)		Types of FracturesSalter-Harris Fracture Types	Illustrations-40

ii ICD-10-CM 2026

How to Use ICD-10-CM Expert for Physicians 2026

Introduction

ICD-10-CM Expert for Physicians: The Complete Official Code Set is your definitive coding resource, combining the work of the National Center for Health Statistics (NCHS), Centers for Medicare and Medicaid Services (CMS), American Hospital Association (AHA), and Optum experts to provide the information you need for coding accuracy.

The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), is an adaptation of ICD-10, copyrighted by the World Health Organization (WHO). The development and maintenance of this clinical modification (CM) is the responsibility of the NCHS as authorized by WHO. Any new concepts added to ICD-10-CM are based on an established update process through the collaboration of WHO's Update and Revision Committee and the ICD-10-CM Coordination and Maintenance Committee.

In addition to the ICD-10-CM classification, other official government source information has been included in this manual. Depending on the source, updates to information may be annual or quarterly. This manual provides the most current information that was available at the time of publication. For updates to the source documents that may have occurred after this manual was published, please refer to the following:

 NCHS, International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)

https://www.cms.gov/medicare/coding-billing/icd-10-codes/2025-icd-10-cm

- CMS Integrated Outpatient Code Editor (IOCE), version 25.2
 https://www.cms.gov/Medicare/Coding/OutpatientCodeEdit/OCEQtrReleaseSpecs.html
- CMS-HCC Risk Adjustment Model, version 28
- CMS ESRD-HCC Risk Adjustment Model, version 24
- CMS RxHCC Risk Adjustment Model, version 08
 https://www.cms.gov/Medicare/Health-

Plans/MedicareAdvtgSpecRateStats/Risk-Adjustors.html

- HHS-HCC Commercial Risk Adjustment Model, version 07 https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance
- CMS Quality Payment Program (QPP)
 https://qpp.cms.gov/mips/explore-measures
- AHA Coding Clinics

https://www.codingclinicadvisor.com/

Significant updates to this manual will be provided on our product updates page at Optumcoding.com, which can be accessed at the following:

https://www.optumcoding.com/ProductUpdates/ Password: XXXXXX

The official NCHS ICD-10-CM classification includes three main sections: the guidelines, the indexes, and the tabular list, all of which make up the bulk of this coding manual. To complement the classification, Optum's coding experts have incorporated Medicare-related coding edits and proprietary features, such as supplementary notations, coding tools, and appendixes, into a comprehensive and easy-to-use reference. This publication is organized as follows:

What's New for 2025

This section provides a high-level overview of the code changes made for fiscal 2025. The list of codes provided identifies new, revised, and deleted codes. Asterisked codes identify prior midyear changes that were made to

the classification, effective April 1, 2024. All changes are based on official addenda, provided by the NCHS.

Conversion Table

The conversion table was developed by NCHS to help facilitate data retrieval as new codes are added to the ICD-10-CM classification. This table provides a crosswalk from each fiscal 2025 new code to the equivalent code(s) assigned, prior to October 1, 2024, for that diagnosis or condition. Asterisked codes identify prior midyear additions, effective April 1, 2024. For the full conversion table, refer to the Conversion Table zip file at https://www.cms.gov/medicare/coding-billing/icd-10-codes/2025-icd-10-cm.

10 Steps to Correct Coding

This step-by-step tutorial walks the coder through the process of finding the correct code — from locating the code in the official indexes to verifying the code in the tabular section — while following applicable conventions, guidelines, and instructional notes. Specific examples are provided with detailed explanations of each coding step along with advice for proper sequencing.

Official ICD-10-CM Guidelines for Coding and Reporting

This section provides the full official conventions and guidelines regulating the appropriate assignment and reporting of ICD-10-CM codes. These conventions and guidelines are published by the U.S. Department of Health and Human Services (DHHS) and approved by the cooperating parties (American Health Information Management Association [AHIMA], NCHS, Centers for Disease Control and Prevention [CDC], and the American Hospital Association [AHA]).

Indexes

Index to Diseases and Injuries

The Index to Diseases and Injuries is arranged in alphabetic order by terms specific to a disease, condition, illness, injury, eponym, or abbreviation as well as terms that describe circumstances other than a disease or injury that may require attention from a health care professional.

Neoplasm Table

The Neoplasm Table is arranged in alphabetic order by anatomical site. Codes are then listed in individual columns based upon the histological behavior (malignant, in situ, benign, uncertain, or unspecified) of the neoplasm.

Table of Drugs and Chemicals

The Table of Drugs and Chemicals is arranged in alphabetic order by the specific drug or chemical name. Codes are listed in individual columns based upon the associated intent (poisoning, adverse effect, or underdosing). Drugs with an asterisk identify substances added to the table by Optum subject matter experts.

External Causes Index

The External Causes Index is arranged in alphabetic order by main terms that describe the cause, the intent, the place of occurrence, the activity, and the status of the patient at the time the injury occurred or health condition arose.

ICD-10-CM 2026

ICD-10-CM Index to Diseases and Injuries

	Abnormal, abnormality, abnormalities — continued A
A	blood level — continued
Aarskog's syndrome Q87.19	lithium R78.89 magnesium R79.0
Abandonment — see Maltreatment	mineral NEC R79.Ø
Abasia (-astasia) (hysterical) F44.4	zinc R79.0
Abderhalden-Kaufmann-Lignac syndrome (cystinosis) E72.04	blood pressure elevated RØ3.Ø
Abdomen, abdominal — see also condition	low reading (nonspecific) RØ3.1
acute R10.0 angina K55.1	blood sugar R73.09 blood-gas level R79.81
muscle deficiency syndrome Q79.4	bowel sounds R19.15
Abdominalgia — see Pain, abdominal	absent R19.11
Abduction contracture, hip or other joint — see Contraction, joint	hyperactive R19.12 brain scan R94.02
Aberrant (congenital) — see also Malposition, congenital	breathing RØ6.9
adrenal gland Q89.1	caloric test R94.138 cerebrospinal fluid R83.9
artery (peripheral) Q27.8 basilar NEC Q28.1	cytology R83.6
cerebral Q28.3	drug level R83.2
coronary Q24.5 digestive system Q27.8	enzyme level R83.0 hormones R83.1
eye Q15.8	immunology R83.4
lower limb Q27.8	microbiology R83.5
precerebral Q28.1 pulmonary Q25.79	nonmedicinal level R83.3 specified type NEC R83.8
renal Q27.2	chemistry, blood R79.9
retina Q14.1	C-reactive protein R79.82
specified site NEC Q27.8 subclavian Q27.8	drugs — see Findings, abnormal, in blood gas level R79.81
upper limb Q27.8	minerals R79.0
vertebral Q28.1	pancytopenia D61.818
breast Q83.8 endocrine gland NEC Q89.2	PTT R79.1 specified NEC R79.89
hepatic duct Q44.5	toxins — see Findings, abnormal, in blood
pancreas Q45.3	chest sounds (friction) (rales) RØ9.89 chromosome, chromosomal Q99.9
parathyroid gland Q89.2 pituitary gland Q89.2	with more than three X chromosomes, female Q97.1
sebaceous glands, mucous membrane, mouth, congenital	analysis result R89.8
Q38.6 spleen Q89.09	bronchial washings R84.8 cerebrospinal fluid R83.8
subclavian artery Q27.8	cervix uteri NEC R87.89
thymus (gland) Q89.2	nasal secretions R84.8
thyroid gland Q89.2 vein (peripheral) NEC Q27.8	nipple discharge R89.8 peritoneal fluid R85.89
cerebral Q28.3	pleural fluid R84.8
digestive system Q27.8 lower limb O27.8	prostatic secretions R86.8 saliva R85.89
precerebral Q28.1	seminal fluid R86.8
specified site NEC Q27.8	sputum R84.8
upper limb Q27.8 Aberration	synovial fluid R89.8 throat scrapings R84.8
distantial — see Disturbance, visual	vagina R87.89
mental F99 Abetalipoproteinemia E78.6	vulva R87.89 wound secretions R89.8
Abiotrophy R68.89	dicentric replacement Q93.2
Ablatio, ablation	ring replacement Q93.2
retinae — see Detachment, retina Ablepharia, ablepharon Q10.3	sex Q99.8 female phenotype Q97.9
Abnormal, abnormality, abnormalities — see also	specified NÉC Q97.8
Anomaly	male phenotype Q98.9
acid-base balance (mixed) E87.4 albumin R77.0	specified NEC Q98.8 structural male Q98.6
alphafetoprotein R77.2	specified NEC Q99.8
alveolar ridge KØ8.9 anatomical relationship Q89.9	clinical findings NEC R68.89 coagulation D68.9
apertures, congenital, diaphragm Q79.1	newborn, transient P61.6
atrial septal, specified NEC Q21.19	profile R79.1
auditory perception H93.29- diplacusis — see Diplacusis	time R79.1 communication — see Fistula
hyperacusis — see Hyperacusis	conjunctiva, vascular H11.41- ✓
recruitment — see Recruitment, auditory	coronary artery Q24.5
threshold shift — see Shift, auditory threshold autosomes Q99.9	cortisol-binding globulin E27.8 course, eustachian tube Q17.8
fragile site Q95.5	creatinine clearance R94.4
basal metabolic rate R94.8	cytology anus R85.619
biosynthesis, testicular androgen E29.1 bleeding time R79.1	atypical squamous cells cannot exclude high grade
blood amino-acid level R79.83	squamous intraepithelial lesion (ASC-H)
blood level (of) cobalt R79.0	R85.611 atypical squamous cells of undetermined signifi-
copper R79.0	cance (ASC-US) R85.610

```
bnormal, abnormality, abnormalities — continued
 cytology — continued anus — continued
       high grade squamous intraepithelial lesion (HGSIL)
             R85.613
       human papillomavirus (HPV) DNA test
          high risk positive R85.81
          low risk postive R85.82
       inadequate smear R85.615
       low grade squamous intraepithelial lesion (LGSIL)
             R85.612
       satisfactory anal smear but lacking transformation
             zoné R85.616
       specified NEC R85.618
       unsatisfactory smear R85.615
    female genital organs — see Abnormal, Papanicolaou
          (smear)
  lark adaptation curve H53.61
 dentofacial NEC — see Anomaly, dentofacial
  development, developmental Q89.9
    central nervous system Q07.9
 diagnostic imaging
    abdomen, abdominal region NEC R93.5
    biliary tract R93.2
    bladder R93.41
    breast R92.8
    central nervous system NEC R9Ø.89
    cerebrovascular NEC R90.89
    coronary circulation R93.1
    digestive tract NEC R93.3
    gastrointestinal (tract) R93.3
    genitourinary organs R93.89
    head R93.0
    heart R93.1
    intrathoracic organ NEC R93.89
    kidney R93.42- ▼
    limbs R93.6
    liver R93.2
    lung (field) R91.8
    musculoskeletal system NEC R93.7
    renal pelvis R93.41
    retroperitoneum R93.5
    site specified NEC R93.89
    skin and subcutaneous tissue R93.89
    skull R93.Ø
    testis R93.81- 🔽
    ureter R93.41
    urinary organs specified NEC R93.49
 direction, teeth, fully erupted M26.30
 ear ossicles, acquired NEC H74.39- ▼
    ankylosis — see Ankylosis, ear ossicles
    discontinuity — see Discontinuity, ossicles, ear
    partial loss — see Loss, ossicles, ear (partial)
 Ebstein Q22.5
 echocardiogram R93.1
 echoencephalogram R9Ø.81
 echogram — see Abnormal, diagnostic imaging
 electrocardiogram [ECG] [EKG] R94.31
 electroencephalogram [EEG] R94.01
 electrolyte — see Imbalance, electrolyte
 electromyogram [EMG] R94.131
 electro-oculogram [EOG] R94.110
 electrophysiological intracardiac studies R94.39
 electroretinogram [ERG] R94.111
 erythrocytes
    congenital, with perinatal jaundice D58.9
 feces (color) (contents) (mucus) R19.5
 finding — see Findings, abnormal, without diagnosis
    amniotic — see Abnormal, specimen, specified
    cerebrospinal — see Abnormal, cerebrospinal fluid
    peritoneal — see Abnormal, specimen, digestive or-
          gans
    pleural — see Abnormal, specimen, respiratory organs synovial — see Abnormal, specimen, specified
    thorax (bronchial washings) (pleural fluid) — see Ab-
          normal, specimen, respiratory organs
    vaginal — see Abnormal, specimen, female genital
          organs
    teeth KØØ.2
    uterus — see Anomaly, uterus
```

cytologic evidence of malignancy R85.614

iron R79.Ø

Neoplasm Table

	Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior		Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior
Neoplasm, neoplastic							Neoplasm, neoplastic		2 01				
— continued brain — continued							— continued bronchus — continued						
basal ganglia	C71.Ø	C79.31	_	D33.Ø	D43.Ø	D49.6	main	C34.Ø- ✓	C78.Ø- ☑	DØ2.2- ☑	D14.3- ✓	D38.1	D49.1
cerebellopontine angle	C71.6	C79.31	_	D33.1	D43.1	D49.6	middle lobe of lung	C34.2	C78.Ø- ☑	DØ2.21	D14.31	D38.1	D49.1
cerebellum NOS cerebrum	C71.6 C71.0	C79.31 C79.31	_	D33.1 D33.0	D43.1 D43.0	D49.6 D49.6	overlapping	C34.8- ▼			_		_
choroid plexus	C71.7	C79.31	_	D33.1	D43.1	D49.6	lesion upper lobe of		_			_	
corpus callosum corpus striatum	C71.8 C71.0	C79.31 C79.31	_	D33.2 D33.0	D43.2 D43.0	D49.6 D49.6	lung brow	C34.1- ✓ C44.309	C78.Ø- ✓ C79.2	DØ2.2- ✓ DØ4.39	D14.3- ✓ D23.39	D38.1 D48.5	D49.1 D49.2
cortex (cerebral)	C71.Ø	C79.31	_	D33.Ø	D43.Ø	D49.6	basal cell		C/ J.2	5555	523.37	5 10.5	0 1712
frontal lobe globus pallidus	C71.1 C71.0	C79.31 C79.31	_	D33.Ø D33.Ø	D43.0 D43.0	D49.6 D49.6	carcinoma specified type	C44.319	_	_	_	_	_
hippocampus hypothalamus	C71.2 C71.0	C79.31 C79.31	_	D33.Ø D33.Ø	D43.0 D43.0	D49.6 D49.6	NEC squamous cell	C44.399	_	_	-	_	-
internal capsule	C71.Ø	C79.31	_	D33.Ø	D43.0	D49.6	carcinoma	C44.329		_	_	_	_
medulla oblongata	C71.7	C79.31	_	D33.1	D43.1	D49.6	buccal (cavity) commissure	CØ6.9 CØ6.Ø	C79.89 C79.89	DØØ.ØØ DØØ.Ø2	D10.39 D10.39	D37.09 D37.09	D49.0 D49.0
meninges	C7Ø.Ø	C79.32	_	D32.Ø D33.1	D42.Ø D43.1	D49.7 D49.6	groove (lower)						
midbrain occipital lobe	C71.7 C71.4	C79.31 C79.31	_	D33.0	D43.1 D43.0	D49.6 D49.6	(upper) mucosa	CØ6.1 CØ6.0	C79.89 C79.89	DØØ.Ø2 DØØ.Ø2	D10.39 D10.39	D37.Ø9 D37.Ø9	D49.Ø D49.Ø
overlapping lesion	C71.8	C79.31	_	_	_	_	sulcus (lower) (upper)	CØ6.1	C79.89	DØØ.Ø2	D10.39	D37.Ø9	D49.Ø
parietal lobe	C71.3	C79.31	_	D33.Ø	D43.Ø	D49.6	bulbourethral						
peduncle pons	C71.7 C71.7	C79.31 C79.31	_	D33.1 D33.1	D43.1 D43.1	D49.6 D49.6	gland bursa — <i>see</i> Neoplasm,	C68.Ø	C79.19	DØ9.19	D3Ø.4	D41.3	D49.59
stem	C71.7	C79.31	_	D33.1	D43.1	D49.6	connective tissue	576.0	670.00	200	D247	D 40 7	D. 40.00
tapetum temporal lobe	C71.8 C71.2	C79.31 C79.31	_	D33.2 D33.0	D43.2 D43.0	D49.6 D49.6	buttock NEC calf	C76.3 C76.5-▼	C79.89 C79.89	DØ4.5 DØ4.7- ▼	D36.7 D36.7	D48.7 D48.7	D49.89 D49.89
thalamus uncus	C71.Ø C71.2	C79.31 C79.31	_	D33.Ø D33.Ø	D43.Ø D43.Ø	D49.6 D49.6	calvarium	C41.Ø	C79.51	_	D16.4	D48.Ø	D49.2
ventricle (floor)	C71.5	C79.31	_	D33.Ø	D43.Ø	D49.6	calyx, renal canal	C65.	C79.0-₩	DØ9.19	D3Ø.1- ✓	D41.1- ✓	D49.51- ✓
fourth branchial (cleft) (cyst)	C71.7	C79.31	_	D33.1	D43.1	D49.6	anal	C21.1	C78.5	DØ1.3	D12.9	D37.8	D49.Ø
(vestiges)	C1Ø.4	C79.89	DØØ.Ø8	D1Ø.5	D37.05	D49.Ø	auditory (external) — see also						
breast (connective tissue) (glandular							Neoplasm, skin, ear	C44.2Ø- ▼	C79 2	DØ4.2- ▼	D23.2- ▼	D48.5	D49.2
tissue) (soft parts)	C5Ø.9- ▼	C79.81	DØ5 ▼	D24 ▼	D48.6- ▼	D49.3	auricular (external) —	C 1 1.25 12	C, J.2	001.2	D23.2 12	10.5	D 13.2
areola	C5Ø.Ø- ✓	C79.81	DØ5 ✓	D24	D48.6- ✓	D49.3	<i>see also</i> Neoplasm, skin,						
axillary tail central portion	C5Ø.6- ✓ C5Ø.1- ✓	C79.81 C79.81	DØ5 ✓	D24V	D48.6-✓	D49.3 D49.3	ear canaliculi, biliary	C44.2Ø- ☑	C79.2	DØ4.2- ✓	D23.2- ✓	D48.5	D49.2
inner	C5Ø.8- ☑	C79.81	DØ5 ✓	D24	D48.6-₩	D49.3 D49.3	(biliferi)						
lower lower-inner	C5Ø.8- ☑	C79.81	DØ5 ✓	D24 ✓	D48.6-✓	D49.3	(intrahepatic) canthus (eye) (inner)	C22.1	C78.7	DØ1.5	D13.4	D37.6	D49.Ø
quadrant	C5Ø.3- ☑	C79.81	DØ5✓	D24 ✓	D48.6-	D49.3	(outer)	C44.1Ø- ✓	C79.2	DØ4.1- ☑	D23.1- ✓	D48.5	D49.2
lower-outer quadrant	C5Ø.5- ▼	C79.81	DØ5₩	D24	D48.6- ☑	D49.3	basal cell carcinoma	C44.11- ☑	_	_	_	_	_
mastectomy site (skin) — see also							sebaceous cell specified type	C44.13- ☑		_	_	_	_
Neoplasm, breast,							NEC	C44.19- ✓	_	_	_	_	_
skin specified as breast	C44.5Ø1	C79.2	- \ `		_	_	squamous cell carcinoma	C44.12- ▼	_	_	_	_	_
tissue	C5Ø.8- ☑	C79.81		<u> </u>	_	_	capillary — see						
midline nipple	C5Ø.8-✓	C79.81	DØ5 ✓	D24✓	D48.6- ✓ D48.6- ✓	D49.3 D49.3	Neoplasm, connective tissue						
outer	C5Ø.8-▼	C79.81	DØ5₩	D24 ✓	D48.6- ▼	D49.3	caput coli carcinoid — see Tumor,	C18.Ø	C78.5	DØ1.Ø	D12.Ø	D37.4	D49.Ø
overlapping lesion	C5Ø.8- ☑	_		_	_	_	carcinoid						
skin basal cell	C44.5Ø1	C79.2	DØ4.5	D23.5	D48.5	D49.2	cardia (gastric) cardiac orifice	C16.Ø	C78.89	DØØ.2	D13.1	D37.1	D49.Ø
carcinoma	C44.511	- (_	_	_	_	(stomach)	C16.Ø	C78.89	DØØ.2	D13.1	D37.1	D49.Ø
specified type NEC	C44.591	_	_	_	_	_	cardio-esophageal junction	C16.Ø	C78.89	DØØ.2	D13.1	D37.1	D49.Ø
squamous cell							cardio-esophagus carina (bronchus)	C16.Ø C34.Ø- ▼	C78.89 C78.Ø- ☑	DØØ.2 DØ2.2- ▼	D13.1 D14.3- ▼	D37.1 D38.1	D49.0 D49.1
carcinoma tail (axillary)	C44.521 C5Ø.6- ☑	C79.81	 Dø5 ✓	— D24 ✓	— D48.6- ▼	— D49.3	carotid (artery)	C49.Ø	C79.89	 —	D21.Ø	D48.1 ✓	D49.2
upper	C5Ø.8- ☑	C79.81	DØ5 ✓	D24 ✓	D48.6- ✓	D49.3	body carpus (any bone)	C75.4 C4Ø.1- ▼	C79.89 C79.51		D35.5 D16.1- ▼	D44.6	D49.7
upper-inner quadrant	C5Ø.2- ▼	C79.81	DØ5 ▼	D24 ▼	D48.6- ▼	D49.3	cartilage (articular)	C 19.1-	2, 3.31		J 10.1-M		
upper-outer quadrant	C5Ø.4- ▼	C79.81	DØ5 ▼	D24 ▼	D48.6- ▼	D49.3	(joint) NEC — see also Neoplasm,						
broad ligament	C50.4- ☑	C79.81	DØ3M	D24D	D39.8	D49.59	bone arytenoid	C41.9 C32.3	C79.51 C78.39	 DØ2.Ø	D16.9 D14.1	D48.Ø D38.Ø	D49.2 D49.1
bronchiogenic, bronchogenic							arytenoid auricular	C32.3 C49.0	C78.39	DØ2.0 —	D14.1 D21.0	D38.0 D48.1 ☑	D49.1 D49.2
(lung)	C34.9- ▼	C78.Ø- ▼	DØ2.2- ▼	D14.3-▼	D38.1	D49.1	bronchi costal	C34.Ø- ✓ C41.3	C78.39 C79.51		D14.3- ✓ D16.7	D38.1 D48.0	D49.1 D49.2
bronchiole bronchus	C34.9- ✓	C78.Ø- ✓	DØ2.2- ✓ DØ2.2- ✓	D14.3- ✓ D14.3- ✓	D38.1 D38.1	D49.1 D49.1	cricoid	C32.3	C78.39	 DØ2.Ø	D14.1	D38.Ø	D49.1
carina	C34.Ø- ☑	C78.Ø- ☑	DØ2.2- ☑	D14.3- ☑	D38.1	D49.1	cuneiform ear (external)	C32.3 C49.0	C78.39 C79.89	DØ2.Ø	D14.1 D21.0	D38.Ø D48.1 ☑	D49.1 D49.2
lower lobe of lung	C34.3- ▼	C78.Ø- ✓	DØ2.2- ▼	D14.3- ▼	D38.1	D49.1	ensiform	C41.3	C79.51	_	D16.7	D48.Ø	D49.2
<u>,</u>							epiglottis	C32.1	C78.39	DØ2.Ø	D14.1	D38.Ø	D49.1

Table of Drugs and Chemicals

	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	ning, Ilt	Poisoning, Undetermined	rse	r- g		Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	ning, Ilt	Poisoning, Undetermined	rse	7 D
Substance	Poisoning, Accidental (unintentio	Poisoning Intentiona Self-harm	Poisoning Assault	Poisoning, Undetermi	Adverse Effect	Under- dosing	Substance	Poisoning, Accidental (unintentio	Poisoning Intentiona Self-harm	Poisoning, Assault	Poiso Unde	Adverse Effect	Under- dosing
Androstalone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthiolimine	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6
Androstanolone Androsterone	T38.7X1	T38.7X2 T38.7X2	T38.7X3 T38.7X3	T38.7X4 T38.7X4	T38.7X5 T38.7X5	T38.7X6 T38.7X6	Anthralin Anthramycin	T49.4X1 T45.1X1	T49.4X2 T45.1X2	T49.4X3 T45.1X3	T49.4X4 T45.1X4	T49.4X5 T45.1X5	T49.4X6 T45.1X6
Anemone pulsatilla	T62.2X1	T62.2X2	T62.2X3	T62.2X4	—	—	Antiadrenergic NEC	T44.8X1	T44.8X2	T44.8X3	T44.8X4	T44.8X5	T44.8X6
Anesthesia		=	=		=	=	Antiallergic NEC	T45.ØX1	T45.ØX2	T45.ØX3	T45.ØX4	T45.ØX5	T45.ØX6
caudal endotracheal	T41.3X1 T41.0X1	T41.3X2 T41.0X2	T41.3X3 T41.0X3	T41.3X4 T41.0X4	T41.3X5 T41.0X5	T41.3X6 T41.0X6	Antiandrogen NEC Anti-anemic (drug)	T38.6X1 T45.8X1	T38.6X2 T45.8X2	T38.6X3 T45.8X3	T38.6X4 T45.8X4	T38.6X5 T45.8X5	T38.6X6 T45.8X6
epidural	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	(preparation)	143.071	143.072	143.083	143.074	145.085	143.670
inhalation	T41.ØX1	T41.ØX2	T41.ØX3	T41.ØX4	T41.ØX5	T41.ØX6	Antianxiety drug NEC	T43.5Ø1	T43.502	T43.5Ø3	T43.5Ø4	T43.5Ø5	T43.5Ø6
local mucosal	T41.3X1 T41.3X1	T41.3X2 T41.3X2	T41.3X3 T41.3X3	T41.3X4 T41.3X4	T41.3X5 T41.3X5	T41.3X6 T41.3X6	Antiaris toxicaria Antiarteriosclerotic drug	T65.891 T46.6X1	T65.892 T46.6X2	T65.893 T46.6X3	T65.894 T46.6X4	— T46.6X5	— T46.6X6
muscle relaxation	T48.1X1	T48.1X2	T48.1X3	T48.1X4	T48.1X5	T48.1X6	Antiasterioscierotic drug Antiasthmatic drug NEC	T48.6X1	T48.6X2	T48.6X3	T48.6X4	T48.6X5	T48.6X6
nerve blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antibiotic Otic Suspension	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
plexus blocking potentiated	T41.3X1 T41.2Ø1	T41.3X2 T41.2Ø2	T41.3X3 T41.2Ø3	T41.3X4 T41.2Ø4	T41.3X5 T41.2Ø5	T41.3X6 T41.2Ø6	(Solution)* Antibiotic NEC	T36.91	T36.92	T36.93	T36.94	T36.95	T36.96
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	aminoglycoside	T36.5X1	T36.5X2	T36.5X3	T36.5X4	T36.5X5	T36.5X6
general	T41.201	T41.2Ø2	T41.2Ø3	T41.2Ø4	T41.205	T41.206	anticancer	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
local regional	T41.3X1	T41.3X2 T41.3X2	T41.3X3	T41.3X4 T41.3X4	T41.3X5 T41.3X5	T41.3X6 T41.3X6	antifungal antimycobacterial	T36.7X1 T36.5X1	T36.7X2 T36.5X2	T36.7X3 T36.5X3	T36.7X4 T36.5X4	T36.7X5 T36.5X5	T36.7X6 T36.5X6
surface	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	antineoplastic	T45.1X1		T45.1X3	T45.1X4	T45.1X5	T45.1X6
Anesthetic NEC — see also	T41.41	T41.42	T41.43	T41.44	T41.45	T41.46	b-lactam NEC	T36.1X1	T36.1X2	T36.1X3	T36.1X4	T36.1X5	T36.1X6
Anesthesia with muscle relaxant	T41.201	T41.202	T41.203	T41.204	T41.205	T41.2Ø6	cephalosporin (group) chloramphenicol (group)	T36.1X1 T36.2X1	T36.1X2 T36.2X2	T36.1X3 T36.2X3	T36.1X4 T36.2X4	T36.1X5 T36.2X5	T36.1X6 T36.2X6
general	T41.201	T41.2Ø2	T41.203	T41.204	T41.205	T41.206	ENT (group)	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	eye	T49.5X1	T49.5X2	T49.5X3	T49.5X4	T49.5X5	T49.5X6
gaseous NEC general NEC	T41.ØX1 T41.2Ø1	T41.0X2 T41.202	T41.0X3 T41.203	T41.0X4 T41.204	T41.0X5 T41.205	T41.0X6 T41.206	fungicidal (local) intestinal	T49.ØX1 T36.8X1	T49.0X2 T36.8X2	T49.0X3 T36.8X3	T49.ØX4 T36.8X4	T49.ØX5 T36.8X5	T49.ØX6 T36.8X6
halogenated hydrocarbon	T41.ØX1	T41.ØX2	T41.ØX3	T41.ØX4	T41.ØX5	T41.ØX6	local	T49.ØX1	T49.ØX2	T49.ØX3	T49.ØX4	T49.ØX5	T49.ØX6
derivatives NEC							macrolides	T36.3X1	T36.3X2	T36.3X3	T36.3X4	T36.3X5	T36.3X6
infiltration NEC intravenous NEC	T41.3X1 T41.1X1	T41.3X2 T41.1X2	T41.3X3 T41.1X3	T41.3X4 T41.1X4	T41.3X5 T41.1X5	T41.3X6 T41.1X6	polypeptide specified NEC	T36.8X1	T36.8X2 T36.8X2	T36.8X3 T36.8X3	T36.8X4 T36.8X4	T36.8X5 T36.8X5	T36.8X6 T36.8X6
local NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	tetracycline (group)	T36.4X1	T36.4X2	T36.4X3	T36.4X4	T36.4X5	T36.4X6
rectal	T41.201	T41.2Ø2	T41.2Ø3	T41.2Ø4	T41.2Ø5	T41.206	throat	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
general local	T41.201 T41.3X1	T41.2Ø2 T41.3X2	T41.203 T41.3X3	T41.204 T41.3X4	T41.205 T41.3X5	T41.206 T41.3X6	Anticancer agents NEC Anticholesterolemic drug	T45.1X1 T46.6X1	T45.1X2 T46.6X2	T45.1X3 T46.6X3	T45.1X4 T46.6X4	T45.1X5 T46.6X5	T45.1X6 T46.6X6
regional NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	NEC	140.07.1	140.072	140.075	140.074	140.003	140.0/0
spinal NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Anticholinergic NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6
thiobarbiturate topical	T41.1X1 T41.3X1	T41.1X2 T41.3X2	T41.1X3 T41.3X3	T41.1X4 T41.3X4	T41.1X5 T41.3X5	T41.1X6 T41.3X6	Anticholinesterase organophosphorus	T44.ØX1 T44.ØX1	T44.0X2 T44.0X2	T44.0X3 T44.0X3	T44.ØX4 T44.ØX4	T44.ØX5 T44.ØX5	T44.ØX6 T44.ØX6
Aneurine	T45.2X1	T45.2X2	T45.2X3	T45.2X4	T45.2X5	T45.2X6	insecticide	T6Ø.ØX1	T6Ø.ØX2	T6Ø.ØX3	T6Ø.ØX4	—	—
Angeliq*	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6	nerve gas	T59.891	T59.892	T59.893	T59.894		
Angio-Conray Angiotensin	T5Ø.8X1 T44.5X1	T5Ø.8X2 T44.5X2	T5Ø.8X3 T44.5X3	T5Ø.8X4 T44.5X4	T5Ø.8X5 T44.5X5	T50.8X6 T44.5X6	reversible ophthalmological	T44.ØX1 T49.5X1	T44.ØX2 T49.5X2	T44.ØX3 T49.5X3	T44.ØX4 T49.5X4	T44.ØX5 T49.5X5	T44.ØX6 T49.5X6
Angiotensinamide	T44.991	T44.992	T44.993	T44,994	T44.995	T44.996	Anticoagulant NEC	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516
Anhydrohydroxy-progesterone	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6	Antagonist	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6
Anhydron Anileridine	T5Ø.2X1 T4Ø.491	T5Ø.2X2 T4Ø.492	T5Ø.2X3 T4Ø.493	T5Ø.2X4 T4Ø.494	T5Ø.2X5 T4Ø.495	T50.2X6 T40.496	Anti-common-cold drug NEC	T48.5X1	T48.5X2	T48.5X3	T48.5X4	T48.5X5	T48.5X6
Aniline (dye) (liquid)	T65.3X1	T65.3X2	T65.3X3	T65.3X4	-	_	Anticonvulsant	T42.71	T42.72	T42.73	T42.74	T42.75	T42.76
analgesic	T39.1X1	T39.1X2	T39.1X3	T39.1X4	T39.1X5		barbiturate	T42.3X1	T42.3X2 T42.3X2	T42.3X3 T42.3X3	T42.3X4	T42.3X5 T42.3X5	T42.3X6 T42.3X6
derivatives, therapeutic NEC	T39.1X1	T39.1X2	T39.1X3	T39.1X4	139.135	T39.1X6	combination (with barbiturate)	T42.3X1	142.382	142.383	T42.3X4	142.385	142.386
vapor	T65.3X1	T65.3X2	T65.3X3	T65.3X4		_	hydantoin	T42.ØX1	T42.ØX2	T42.ØX3	T42.ØX4	T42.ØX5	T42.ØX6
Aniscoropine	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	hypnotic NEC oxazolidinedione	T42.6X1	T42.6X2 T42.2X2		T42.6X4	T42.6X5 T42.2X5	T42.6X6 T42.2X6
Anise oil Anisidine	T47.5X1 T65.3X1	T47.5X2 T65.3X2	T47.5X3 T65.3X3	T47.5X4 T65.3X4	T47.5X5	T47.5X6	pyrimidinedione	T42.2X1 T42.6X1	T42.6X2		T42.2X4 T42.6X4	T42.6X5	T42.6X6
Anisindione	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516	specified NEC	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
Anisotropine methyl-bromide	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	succinimide Antidepressant	T42.2X1 T43.2Ø1	T42.2X2 T43.2Ø2	T42.2X3 T43.2Ø3	T42.2X4 T43.2Ø4	T42.2X5 T43.2Ø5	T42.2X6 T43.206
Anistreplase	T45.611	T45.612	T45.613	T45.614	T45.615	T45.616	monoamine oxidase	T43.1X1	T43.1X2		T43.1X4	T43.1X5	T43.1X6
Anorexiant (central)	T5Ø.5X1	T5Ø.5X2	T5Ø.5X3	T5Ø.5X4	T5Ø.5X5	T5Ø.5X6	inhibitor					T.12.5.	
Anorexic agents Ansaid*	T5Ø.5X1 T39.311	T39.312	T5Ø.5X3 T39.313	T5Ø.5X4 T39.314	T5Ø.5X5 T39.315	T5Ø.5X6 T39.316	selective serotonin norepinephrine reuptake	T43.211	T43.212	T43.213	T43.214	T43.215	T43.216
Ansamycin	T36.6X1	T36.6X2	T36.6X3	T36.6X4	T36.6X5	T36.6X6	inhibitor						
Ant (bite) (sting)	T63.421	T63.422	T63.423	T63.424	— TE 0. 61/15		selective serotonin reuptake	T43.221	T43.222	T43.223	T43.224	T43.225	T43.226
Antabuse Antacid NEC	T5Ø.6X1 T47.1X1	T5Ø.6X2 T47.1X2	T5Ø.6X3 T47.1X3	T5Ø.6X4 T47.1X4	T5Ø.6X5 T47.1X5	T5Ø.6X6 T47.1X6	inhibitor specified NEC	T43.291	T43.292	T43.293	T43.294	T43.295	T43.296
Antagonist	117.17	117.17.2	117.17.5	1 17.17(1	117.17.5	117.170	tetracyclic	T43.Ø21	T43.Ø22	T43.Ø23	T43.024	T43.Ø25	T43.026
Aldosterone	T5Ø.ØX1	T50.0X2	T50.0X3	T50.0X4	T50.0X5	T5Ø.ØX6	triazolopyridine	T43.211	T43.212		T43.214	T43.215	T43.216
alpha-adrenoreceptor anticoagulant	T44.6X1 T45.7X1	T44.6X2 T45.7X2	T44.6X3 T45.7X3	T44.6X4 T45.7X4	T44.6X5 T45.7X5	T44.6X6 T45.7X6	tricyclic Antidiabetic NEC	T43.Ø11 T38.3X1	T43.Ø12 T38.3X2	T43.Ø13 T38.3X3	T43.Ø14 T38.3X4	T43.Ø15 T38.3X5	T43.Ø16 T38.3X6
beta-adrenoreceptor	T44.7X1	T44.7X2	T44.7X3	T44.7X4	T44.7X5	T44.7X6	biguanide	T38.3X1	T38.3X2		T38.3X4	T38.3X5	T38.3X6
extrapyramidal NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	and sulfonyl combined	T38.3X1	T38.3X2		T38.3X4	T38.3X5	T38.3X6
folic acid H2 receptor	T45.1X1 T47.ØX1	T45.1X2 T47.ØX2	T45.1X3 T47.ØX3	T45.1X4 T47.ØX4	T45.1X5 T47.ØX5	T45.1X6 T47.ØX6	combined sulfonylurea	T38.3X1 T38.3X1	T38.3X2 T38.3X2	T38.3X3 T38.3X3	T38.3X4 T38.3X4	T38.3X5 T38.3X5	T38.3X6 T38.3X6
heavy metal	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6	Antidiarrheal drug NEC	T47.6X1	T47.6X2		T47.6X4	T47.6X5	T47.6X6
narcotic analgesic	T5Ø.7X1	T5Ø.7X2	T5Ø.7X3	T5Ø.7X4	T5Ø.7X5	T5Ø.7X6	absorbent	T47.6X1	T47.6X2	T47.6X3	T47.6X4	T47.6X5	T47.6X6
opiate pyrimidine	T5Ø.7X1 T45.1X1	T5Ø.7X2 T45.1X2	T5Ø.7X3 T45.1X3	T5Ø.7X4 T45.1X4	T5Ø.7X5 T45.1X5	T5Ø.7X6 T45.1X6	Anti-D immunoglobulin (human)	T5Ø.Z11	T5Ø.Z12	T5Ø.Z13	T5Ø.Z14	T5Ø.Z15	T5Ø.Z16
serotonin	T46.5X1	T46.5X2	T46.5X3	T46.5X4	T46.5X5	T46.5X6	Antidiphtheria serum	T5Ø.Z11	T5Ø.Z12	T5Ø.Z13	T5Ø.Z14	T5Ø.Z15	T5Ø.Z16
Antazolin (e)	T45.ØX1	T45.ØX2	T45.ØX3	T45.ØX4	T45.ØX5	T45.ØX6	Antidiuretic hormone	T38.891	T38.892	T38.893	T38.894	T38.895	T38.896
Anterior pituitary hormone NEC	T38.811	T38.812	T38.813	T38.814	T38.815	T38.816	Antidote NEC heavy metal	T5Ø.6X1 T45.8X1	T5Ø.6X2 T45.8X2	T5Ø.6X3 T45.8X3	T5Ø.6X4 T45.8X4	T5Ø.6X5 T45.8X5	T5Ø.6X6 T45.8X6
Anthelmintic NEC	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6	Antidysrhythmic NEC	T46.2X1			T46.2X4	T46.2X5	

ICD-10-CM Tabular List of Diseases and Injuries

Chapter 1. Certain Infectious and Parasitic Diseases (AØØ-B99), UØ7.1, UØ9.9

Chapter-specific Guidelines with Coding Examples

The chapter-specific guidelines from the ICD-10-CM Official Guidelines for Coding and Reporting have been provided below. Along with these guidelines are coding examples, contained in the shaded boxes, that have been developed to help illustrate the coding and/or sequencing guidance found in these guidelines.

a. Human immunodeficiency virus (HIV) infections

1) Code only confirmed cases

Code only confirmed cases of HIV infection/illness. This is an exception to the hospital inpatient guideline Section II, H.

In this context, "confirmation" does not require documentation of positive serology or culture for HIV; the provider's diagnostic statement that the patient is HIV positive or has an HIV-related illness is sufficient.

Patient being seen for hypothyroidism with possible HIV infection

EØ3.9 Hypothyroidism, unspecified

Explanation: Only the hypothyroidism is coded in this scenario because it has not been confirmed that an HIV infection is present.

2) Selection and sequencing of HIV codes

(a) Patient admitted for HIV-related condition

If a patient is admitted for an HIV-related condition, the principal diagnosis should be B2Ø, Human immunodeficiency virus [HIV] disease followed by additional diagnosis codes for all reported HIV-related conditions.

An exception to this guideline is if the reason for admission is hemolytic-uremic syndrome associated with HIV disease. Assign code D59.31, Infection-associated hemolytic-uremic syndrome, followed by code B20, Human immunodeficiency virus [HIV] disease.

HIV with CMV

B2Ø Human immunodeficiency virus [HIV] disease

B25.9 Cytomegaloviral disease, unspecified

Explanation: Cytomegaloviral infection is an HIV related condition, so the HIV diagnosis code is reported first, followed by the code for the CMV.

(b) Patient with HIV disease admitted for unrelated condition

If a patient with HIV disease is admitted for an unrelated condition (such as a traumatic injury), the code for the unrelated condition (e.g., the nature of injury code) should be the principal diagnosis. Other diagnoses would be B2Ø followed by additional diagnosis codes for all reported HIV-related conditions.

Sprain of the internal collateral ligament, right ankle; HIV

S93.491A Sprain of other ligament of right ankle, initial

B20 Human immunodeficiency virus [HIV] disease

Explanation: The ankle sprain is not related to HIV, so it is the first-listed diagnosis code, and HIV is reported secondarily.

(c) Whether the patient is newly diagnosed

Whether the patient is newly diagnosed or has had previous admissions/encounters for HIV conditions is irrelevant to the sequencing decision.

Newly diagnosed multiple cutaneous Kaposi's sarcoma lesions in previously diagnosed HIV disease

B2Ø Human immunodeficiency virus [HIV] disease

C46.Ø Kaposi's sarcoma of skin

Explanation: Even though the HIV was diagnosed on a previous encounter, it is still sequenced first when coded with an HIV-related condition. Kaposi's sarcoma is an HIV-related condition.

(d) Asymptomatic human immunodeficiency virus

Z21, Asymptomatic human immunodeficiency virus [HIV] infection status, is to be applied when the patient without any documentation of symptoms is listed as being "HIV positive," "known HIV," "HIV test positive," or similar terminology. Do not use this code if the term "AIDS" or "HIV disease" is used or if the patient is treated for any

HIV-related illness or is described as having any condition(s) resulting from his/her HIV positive status; use B2Ø in these cases.

(e) Patients with inconclusive HIV serology

Patients with inconclusive HIV serology, but no definitive diagnosis or manifestations of the illness, may be assigned code R75, Inconclusive laboratory evidence of human immunodeficiency virus [HIV].

(f) Previously diagnosed HIV-related illness

Patients with any known prior diagnosis of an HIV-related illness should be coded to B2Ø. Once a patient has developed an HIV-related illness, the patient should always be assigned code B2Ø on every subsequent admission/encounter. Patients previously diagnosed with any HIV illness (B2Ø) should never be assigned to R75 or Z21, Asymptomatic human immunodeficiency virus [HIV] infection status.

(g) HIV infection in pregnancy, childbirth and the puerperium

During pregnancy, childbirth or the puerperium, a patient admitted (or presenting for a health care encounter) because of an HIV-related illness should receive a principal diagnosis code of O98.7-, Human immunodeficiency [HIV] disease complicating pregnancy, childbirth and the puerperium, followed by B2Ø and the code(s) for the HIV-related illness(es). Codes from Chapter 15 always take sequencing priority.

Patients with asymptomatic HIV infection status admitted (or presenting for a health care encounter) during pregnancy, childbirth, or the purperium should receive codes of O98.7- and Z21.

(h) Encounters for testing for HIV

If a patient is being seen to determine his/her HIV status, use code Z11.4, Encounter for screening for human immunodeficiency virus (HIV). Use additional codes for any associated high-risk behavior, if applicable.

If a patient with signs or symptoms is being seen for HIV testing, code the signs and symptoms. An additional counseling code Z71.7, Human immunodeficiency virus [HIV] counseling, may be used if counseling is provided during the encounter for the test.

When a patient returns to be informed of his/her HIV test results and the test result is negative, use code Z71.7, Human immunodeficiency virus [HIV] counseling.

If the results are positive, see previous guidelines and assign codes as appropriate.

(i) HIV managed by antiretroviral medication

If a patient with documented HIV disease, HIV-related illness or AIDS is currently managed on antiretroviral medications, assign code B2Ø, Human immunodeficiency virus [HIV] disease. Code Z79.899, Other long term (current) drug therapy, may be assigned as an additional code to identify the long-term (current) use of antiretroviral medications.

(j) Encounter for HIV Prophylaxis Measure

When a patient is seen for administration of pre-exposure prophylaxis medication for HIV, assign code Z29.81, Encounter for HIV pre-exposure prophylaxis. Pre-exposure prophylaxis (PrEP) is intended to prevent infection in people who are at risk for getting HIV through sex or injection drug use. Any risk factors for HIV should also be coded.

b. Infectious agents as the cause of diseases classified to other chapters

Certain infections are classified in chapters other than Chapter 1 and no organism is identified as part of the infection code. In these instances, it is necessary to use an additional code from Chapter 1 to identify the organism. A code from category B95, Streptococcus, Staphylococcus, and Enterococcus as the cause of diseases classified to other chapters, B96, Other bacterial agents as the cause of diseases classified to other chapters, or B97, Viral agents as the cause of diseases classified to other chapters, is to be used as an additional code to identify the organism. An instructional note will be found at the infection code advising that an additional organism code is required.

Acute E. coli cystitis

N3Ø.ØØ Acute cystitis without hematuria

B96.2Ø Unspecified Escherichia coli [E.coli] as the cause of diseases classified elsewhere

Explanation: An instructional note under the category for the cystitis indicates to code also the specific organism.

ICD-10-CM 2026 445

Chapter 5. Mental, Behavioral and Neurodevelopmental Disorders

F16.921 Hallucinogen use, unspecified with F17.203 Nicotine dependence unspecified, with HCC ESR COM intoxication with delirium withdrawal Other hallucinogen intoxication delirium Tobacco withdrawal Nicotine dependence, unspecified, with F16.929 Hallucinogen use, unspecified with F17.208 other nicotine-induced disorders intoxication, unspecified F17.209 Nicotine dependence, unspecified, with F16.94 Hallucinogen use, unspecified with unspecified nicotine-induced disorders hallucinogen-induced mood disorder HCC ESR COM √6th F17.21 Nicotine dependence, cigarettes Other hallucinogen induced bipolar or related disorder, F17.21Ø Nicotine dependence, cigarettes, without use disorder Other hallucinogen induced depressive disorder, uncomplicated without use disorder AHA: 2017,2Q,28-29 Phencyclidine induced bipolar or related disorder, F17.211 Nicotine dependence, cigarettes, in without use disorder remission Phencyclidine induced depressive disorder, without Tobacco use disorder, cigarettes, mild, in use disorder early remission Hallucinogen use, unspecified with F16.95 Tobacco use disorder, cigarettes, mild, in hallucinogen-induced psychotic disorder sustained remission F16.950 Hallucinogen use, unspecified with Tobacco use disorder, cigarettes, moderate, hallucinogen-induced psychotic disorder in early remission CC ESR COM obacco use disorder, cigarettes, moderate, with delusions F16.951 Hallucinogen use, unspecified with in sustained remission Tobacco use disorder, cigarettes, severe, in hallucinogen-induced psychotic disorder early remission with hallucinations HCC ESR COM Tobacco use disorder, cigarettes, severe, in F16.959 Hallucinogen use, unspecified with ustained remission hallucinogen-induced psychotic disorder, F17.213 Nicotine dependence, cigarettes, with unspecified C ESR COM vithdrawal Other hallucinogen induced psychotic F17.218 Nicotine dependence, cigarettes, with disorder, without use disorder other nicotine-induced disorders Phencyclidine induced psychotic disorder, F17.219 Nicotine dependence, cigarettes, with without use disorder unspecified nicotine-induced disorders Hallucinogen use, unspecified with other specified F16.98 √6th F17.22 Nicotine dependence, cnewing tobacco hallucinogen-induced disorder F17.220 Nicotine dependence, chewing tobacco, F16.98Ø Hallucinogen use, unspecified with hallucinogen-induced anxiety uncomplicated disorder F17.221 Nicotine dependence, chewing tobacco, in Other hallucinogen-induced anxiety remission disorder, without use disorder Tobacco use disorder, chewing tobacco, Phencyclidine induced anxiety disorder mild, in early remission without use disorder Tobacco use disorder, chewing tobacco, mild, in sustained remission F16.983 Hallucinogen use, unspecified with hallucinogen persisting perception Tobacco use disorder, chewing tobacco. HCC ESR CO disorder (flashbacks) moderate, in early remission Tobacco use disorder, chewing tobacco, Hallucinogen use, unspecified with other F16.988 moderate, in sustained remission hallucinogen-induced Tobacco use disorder, chewing tobacco, disorder ESR COM severe, in early remission Hallucinogen use, unspecified with unspecified Tobacco use disorder, chewing tobacco, hallucinogen-induced disorder severe, in sustained remission **▼4th** F17 Nicotine dependence F17.223 Nicotine dependence, chewing tobacco, **EXCLUDES 1** history of tobacco dependence (Z87.891) with withdrawal tobacco use NOS (Z72.Ø) F17.228 Nicotine dependence, chewing tobacco, tobacco use (smoking) during pregnancy, childbirth and the with other nicotine-induced disorders puerperium (O99.33-) F17.229 Nicotine dependence, chewing tobacco, with unspecified nicotine-induced toxic effect of nicotine (T65.2disorders AHA: 2013,40,108-109 √6th F17.29 Nicotine dependence, other tobacco product **√5** F17.2 Nicotine dependence F17.29Ø Nicotine dependence, other tobacco F17.20 Nicotine dependence, unspecified product, uncomplicated F17.200 Nicotine dependence, unspecified, AHA: 2017,2Q,28-29 uncomplicated F17.291 Nicotine dependence, other tobacco Tobacco use disorder, mild product, in remission Tobacco use disorder, moderate Tobacco use disorder, other tobacco Tobacco use disorder, severe product, mild, in early remission AHA: 2016,1Q,36 Tobacco use disorder, other tobacco IP: Assign when provider documentation product, mild, in sustained remission indicates "smoker" without further Tobacco use disorder, other tobacco specification. product, moderate, in early remission F17.201 Nicotine dependence, unspecified, in Tobacco use disorder, other tobacco remission product, moderate, in sustained Tobacco use disorder, mild, in early remission Tobacco use disorder, other tobacco Tobacco use disorder, mild, in sustained product, severe, in early remission remission Tobacco use disorder, other tobacco Tobacco use disorder, moderate, in early product, severe, in sustained remission remission F17.293 Nicotine dependence, other tobacco Tobacco use disorder, moderate, in product, with withdrawal sustained remission F17.298 Nicotine dependence, other tobacco Tobacco use disorder, severe, in early product, with other nicotine-induced remission disorders Tobacco use disorder, severe, in sustained Nicotine dependence, other tobacco remission product, with unspecified nicotine-induced disorders



Pediatric: 0-17

HCC Rx ESR COM

Chapter 9. Diseases of the Circulatory System 122.8 Subsequent ST elevation (STEMI) myocardial infarction of other 124 Other acute ischemic heart diseases C Rx ESR COM EXCLUDES 1 anaina pectoris (120.-) Subsequent acute transmural myocardial infarction of other sites transient myocardial ischemia in newborn (P29.4) Subsequent apical-lateral transmural (Q wave) myocardial EXCLUDES 2 non-ischemic myocardial injury (I5A) infarction (acute) 124.0 Acute coronary thrombosis not resulting in myocardial Subsequent basal-lateral transmural (Q wave) myocardial infarction infarction (acute) Acute coronary (artery) (vein) embolism not resulting in Subsequent high lateral transmural (Q wave) myocardial infarction myocardial infarction (acute) Acute coronary (artery) (vein) occlusion not resulting in myocardial Subsequent posterior (true) transmural (Q wave) myocardial infarction infarction (acute) Acute coronary (artery) (vein) thromboembolism not resulting in Subsequent posterobasal transmural (Q wave) myocardial myocardial infarction infarction (acute) **EXCLUDES 1** atherosclerotic heart disease (125.1-) Subsequent posterolateral transmural (Q wave) myocardial AHA: 2013,1Q,24 infarction (acute) 124.1 Dressler's syndrome Subsequent posteroseptal transmural (Q wave) myocardial Postmyocardial infarction syndrome infarction (acute) Subsequent septal NOS transmural (Q wave) myocardial infarction **EXCLUDES 1** postinfarction angina (123.7) **DEF:** Fever, leukocytosis, chest pain, evidence of pericarditis, Subsequent transmural (Q wave) myocardial infarction (acute)(of) pleurisy, and pneumonia occurring days or weeks after a lateral (wall) NOS myocardial infarction. 122.9 Subsequent ST elevation (STEMI) myocardial infarction of √5th 124.8 Other forms of acute ischemic heart disease unspecified site **EXCLUDES 1** myocardial infarction due to demand ischemia (I21.A1) Subsequent acute myocardial infarction of unspecified site AHA: 2023,4Q,25-26; 2019 4Q,53; 2017,4Q,13 Subsequent myocardial infarction (acute) NOS Acute coronary microvascular 123 Certain current complications following ST elevation (STEMI) and dysfunction non-ST elevation (NSTEMI) myocardial infarction (within the 28 day Acute (presentation of) coronary microvascular disease period) 124.89 Other forms of acute ischemic heart **DEF:** ST elevation myocardial infarction: Complete obstruction of one or Acute ischemic heart disease, unspecified more coronary arteries causing decreased blood flow (ischemia) and **EXCLUDES 1** ischemic heart disease (chronic) NOS (125.9) necrosis of myocardial muscle cells. **DEF:** Non-ST elevation myocardial infarction: Partial obstruction of one 125 Chronic ischemic heart disease or more coronary arteries that causes decreased blood flow (ischemia) Use additional code to iden and may cause partial thickness necrosis of myocardial muscle cells chronic total occlusion of coronary artery (125.82) 123.Ø Hemopericardium as current complication following acute exposure to environmental tobacco smoke (Z77.22) myocardial infarction CC Rx ESR COM 🔼 history of tobacco dependence (Z87.891) **EXCLUDES 1** hemopericardium not specified as current complication occupational exposure to environmental tobacco smoke (Z57.31) following acute myocardial infarction (131.2) tobacco dependence (F17.-) tobacco use (Z72.Ø) 123.1 Atrial septal defect as current complication following acute EXCLUDES 2 non-ischemic myocardial injury (I5A) myocardial infarction HCC RX ESR COM AHA: 2022,4Q,20-21 **EXCLUDES 1** acquired atrial septal defect not specified as current complication following acute myocardial 125.1 Atherosclerotic heart disease of native coronary artery infarction (I51.0) Atherosclerotic cardiovascular disease Coronary (artery) atheroma 123.2 Ventricular septal defect as current complication following acute myocardial infarction Coronary (artery) atherosclerosis Coronary (artery) disease **EXCLUDES 1** acquired ventricular septal defect not specified as Coronary (artery) sclerosis urrent complication following acute myocardial Use additional code, if applicable, to identify: infarction (I51.0) coronary atherosclerosis due to calcified coronary lesion (I25.84) 123.3 Rupture of cardiac wall without hemopericardium as current coronary atherosclerosis due to lipid rich plaque (125.83) complication following acute myocardial atheroembolism (175.-) CC Rx ESR COM A infarction atherosclerosis of coronary artery bypass graft(s) and 123.4 Rupture of chordae tendineae as current complication transplanted heart (125.7-) Rx ESR COM following acute myocardial infarction **EXCLUDES 1** rupture of chordae tendineae not specified as current **Atheromas** complication following acute myocardial Atheromas (fatty tissue infarction (151.1) Lumer and/or plaque) Rupture of papillary muscle as current complication following acute myocardial infarction **EXCLUDES 1** rupture of papillary muscle not specified as current complication following acute myocardial infarction (I51.2) Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial Atherosclerotic heart disease of native coronary infarction thrombosis of atrium, auricular appendage, and artery without angina pectoris Atherosclerotic heart disease NOS ventricle not specified as current complication following acute myocardial infarction (I51.3) **AHA:** 2024,1Q,28; 2021,3Q,6-7; 2015,2Q,16; 2012,4Q,92 Atherosclerotic heart disease of native coronary 125.11 123.7 Postinfarction angina HCC Rx ESR COM A artery with angina pectoris AHA: 2015.20.16 AHA: 2024,1Q,28 TIP: When postinfarction angina occurs with atherosclerotic coronary artery disease, code both I23.7 and I25.118 for atherosclerotic disease with other forms of angina pectoris.

125.110 Atherosclerotic heart disease of native

OPP

coronary artery with unstable angina pectoris HCC Rx ESR COM A

EXCLUDES 1 unstable angina without atherosclerotic heart disease (120.0)

Additional Character Required ICD-10-CM 2026

infarction



123.8 Other current complications following acute myocardial

CC Rx ESR COM A

Muscle/Tendon Table

ICD-10-CM categorizes certain muscles and tendons in the upper and lower extremities by their action (e.g., extension, flexion), their anatomical location (e.g., posterior, anterior), and/or whether they are intrinsic or extrinsic to a certain anatomical area. The Muscle/Tendon Table is provided at the beginning of chapters 13 and 19 as a resource to help users when code selection depends on one or more of these characteristics. A **TIP** has been placed at those categories and/or subcategories that relate to this table. Please note that this table is not all-inclusive, and proper code assignment should be based on the provider's documentation.

Body Region	Muscle	Extensor Tendon	Flexor Tendon	Other Tendon
Shoulder			'	
	Deltoid	Posterior deltoid	Anterior deltoid	
	Rotator cuff			
	Infraspinatus			Infraspinatus
	Subscapularis			Subscapularis
	Supraspinatus			Supraspinatus
	Teres minor			Teres minor
	Teres major	Teres major	_	
Upper arm		,		L
	Anterior muscles			
	Biceps brachii — long head		Biceps brachii — long head	
	Biceps brachii — short head		Biceps brachii — short head	
	Brachialis		Brachialis	
	Coracobrachialis		Coracobrachialis	
	Posterior muscles			
	Triceps brachii	Triceps brachii		
Forearm	The cops where the co	, meeps side		
	Anterior muscles			
	Flexors			
	Deep			
	Flexor digitorum profundus		Flexor digitorum profundus	
	Flexor pollicis longus		Flexor pollicis longus	
	Intermediate		Trexor politers fortigus	
	Flexor digitorum superficialis		Flexor digitorum superficialis	
	Superficial		Trexor digitorum supernicians	
	Flexor carpi radialis		Flexor carpi radialis	
	Flexor carpi ulnaris		Flexor carpi ulnaris	
	Palmaris longus		Palmaris longus	
	Pronators			Dropator guadratus
	Pronator quadratus			Pronator quadratus
	Pronator teres			Pronator teres
	Posterior muscles			
	Extensors	,		
	Deep			AL L . HILL
	Abductor pollicis longus			Abductor pollicis longus
	Extensor indicis	Extensor indicis		
	Extensor pollicis brevis	Extensor pollicis brevis		
	Extensor pollicis longus	Extensor pollicis longus		
	Superficial			
	Brachioradialis			Brachioradialis
	Extensor carpi radialis brevis	Extensor carpi radialis brevis		
	Extensor carpi radialis longus	Extensor carpi radialis longus		
	Extensor carpi ulnaris	Extensor carpi ulnaris		
	Extensor digiti minimi	Extensor digiti minimi		
	Extensor digitorum	Extensor digitorum		
	Anconeus	Anconeus		
	Supinator			Supinator

ICD-10-CM 2026 979

Chapter 21. Factors Influencing Health Status and **Contact With Health Services (Z00-Z99)**

Z codes represent reasons for encounters. A corresponding procedure code must accompany a Z code if a procedure is performed. Categories ZØØ-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00-Y89 are recorded as "diagnoses" or "problems." This can arise in two main

(a) When a person who may or may not be sick encounters the health services for some specific purpose, such as to receive limited care or service for a current condition, to donate an organ or tissue, to receive prophylactic vaccination (immunization), or to discuss a problem which is in itself not a disease or injury.

(b) When some circumstance or problem is present which influences the person's health status but is not in itself a current illness or injury.

AHA: 2018,4Q,60-61

This chapter contains the following blocks:

700-713 Persons encountering health services for examinations Genetic carrier and genetic susceptibility to disease Z14-Z15 Resistance to antimicrobial drugs Z16

717

▶Estrogen, and other hormones and factors receptor status◀

Z18 Retained foreign body fragments Z19 Hormone sensitivity malignancy status

720-729 Persons with potential health hazards related to communicable diseases

Z3Ø-Z39 Persons encountering health services in circumstances related to reproduction

Z4Ø-Z53 Encounters for other specific health care

Persons with potential health hazards related to socioeconomic and Z55-Z65 psychosocial circumstances

Z66 Do not resuscitate status

Z67 Blood type

Z68 Body mass index (BMI)

Z69-Z76 Persons encountering health services in other circumstances 777-799 Persons with potential health hazards related to family and personal history and certain conditions influencing health status

Persons encountering health services for examinations (ZØØ-Z13)

Nonspecific abnormal findings disclosed at the time of these examinations are classified to categories R7Ø-R94.

EXCLUDES 1 examinations related to pregnancy and reproduction (Z3Ø-Z36, Z39.-

ZØØ Encounter for general examination without complaint, suspected or reported diagnosis

EXCLUDES 1 encounter for examination for administrative purposes (ZØ2.-) encounter for pre-procedural examinations (ZØ1.81-) special screening examinations (Z11-Z13)

AHA: 2017,40,95

ZØØ.Ø Encounter for general adult medical examination

Encounter for adult periodic examination (annual) (physical) and any associated laboratory and radiologic examinations

EXCLUDES 1 encounter for examination of sign or symptom - code to sign or symptom

general health check-up of infant or child (ZØØ.12.-)

Z00.00 Encounter for general adult medical examination without abnormal finding

Encounter for adult health check-up NOS

Encounter for general adult medical examination with abnormal findings

Use additional code to identify abnormal findings AHA: 2016,10,35-36

Z00.1 Encounter for newborn, infant and child health examinations

ZØØ.11 Newborn health examination

Health check for child under 29 days old Use additional code to identify any abnormal findings

EXCLUDES 1 health check for child over 28 days old (700.12-)

ZØØ.11Ø Health examination for newborn under 8 days old

Health check for newborn under 8 days old ZØØ.111 Health examination for newborn 8 to 28

days old Health check for newborn 8 to 28 days old Newborn weight check

```
ICD-10-CM 2026
       ZØØ.12 Encounter for routine child health examination
                        Health check (routine) for child over 28 days old
                        Immunizations appropriate for age
                        Routine developmental screening of infant or child
                        Routine vison and hearing testing
                        EXCLUDES 1 health check for child under 29 days old
                                         (ZØØ.11-)
                                     health supervision of foundling or other
                                         healthy infant or child (Z76.1-Z76.2)
                                     newborn health examination (ZØØ.11-)
                        AHA: 2018,40,36
                      ZØØ.121 Encounter for routine child health
                                 examination with abnormal
                                 findings
                                   Use additional code to identify abnormal
                                       findings
                                   AHA: 2016,10,34-35
                      ZØØ.129 Encounter for routine child health
                                 examination without abnormal
                                                                     PDx P
                                   dinas
                                  Encounter for routine child health
                                       examination NOS
                                   AHA: 2016 1Q,34
     Z00.2 Encounter for examination for period of rapid growth in
             childhood
     Z00.3 Encounter for examination for adolescent development
             state
               Encounter for puberty development state
     Z00.5 Encounter for examination of potential donor of organ and
     Z00.6 Encounter for examination for normal comparison and control
             in clinical research program
               Examination of participant or control in clinical research program
             Encounter for examination for period of delayed growth in
             ZØØ.7Ø Encounter for examination for period of delayed
                      growth in childhood without abnormal
                      findings
             ZØØ.71
                      Encounter for examination for period of delayed
                      growth in childhood with abnormal
                      findings
                                                                     PDx P
                        Use additional code to identify abnormal findings
            Encounter for other general examination
               Encounter for health examination in population surveys
ZØ1 Encounter for other special examination without complaint,
     suspected or reported diagnosis
       INCLUDES routine examination of specific system
                   Codes from category ZØ1 represent the reason for the
                   encounter. A separate procedure code is required to identify
                   any examinations or procedures performed
       EXCLUDES 1
                   encounter for examination for administrative purposes (ZØ2.-)
                   encounter for examination for suspected conditions, proven
                        not to exist (ZØ3.-)
                   encounter for laboratory and radiologic examinations as a
                       component of general medical examinations (ZØØ.Ø-)
                   encounter for laboratory, radiologic and imaging examinations
                        for sign(s) and symptom(s) - code to the sign(s) or
                        symptom(s)
       EXCLUDES 2 screening examinations (Z11-Z13)
▼5º ZØ1.Ø Encounter for examination of eyes and vision
               EXCLUDES 1 examination for driving license (ZØ2.4)
             ZØ1.ØØ
                      Encounter for examination of eyes and vision without
                      abnormal findings
                        Encounter for examination of eyes and vision NOS
             ZØ1.Ø1
                      Encounter for examination of eyes and vision with
                      abnormal findings
                        Use additional code to identify abnormal findings
                        AHA: 2016,4Q,21
                      Encounter for examination of eyes and vision
       √6<sup>th</sup> ZØ1.Ø2
```

following failed vision screening

EXCLUDES 1 encounter for examination of eyes and vision with abnormal findings (ZØ1.Ø1) encounter for examination of eyes and vision without abnormal findings (ZØ1.ØØ)

AHA: 2019,40,20

ZØ1.Ø2Ø Encounter for examination of eyes and vision following failed vision screening without abnormal findings

Rx HCC HCC CMS-HCC ESR ESRD HCC Commercial HCC

Primary Dx Only

Newborn: 0

Pediatric: 0-17

Maternity: 9-64

Adult: 15-124

Appendix C: Z Codes for Long-Term Drug Use with Associated Drugs

This resource correlates the Z codes that are used to identify current long-term drug use with a list of drugs that are typically categorized to that class of drug. These lists are not all-inclusive, providing only the more commonly used drugs.

Z79.01 Long term (current) use of anticoagulants

Arixtra Defencath Eliquis Fragmin Heparin Jantoven Lovenox Pradaxa Savavsa Warfarin Xarelto

Long term (current) use of antithrombotics/ antiplatelets

> Aggrastat Angiomax Argatroban Brilinta Clopidogrel bisulfate

Effient **Eptifibatide** Persantine Plavix Prasugrel

Z79.1 Long term (current) use of non-steroidal anti-inflammatories

(NSAID) Advil Aleve Anaprox DS Arthrotec Caldolor

Cambia Celebrex Daypro Duexis Feldene Ibuprofen Indocin. Mobic Motrin IB

Nabumetone Nalfon Naprelan

Naprosyn NeoProfen Ponstel

Voltaren Arthritis Pain Zipsor

Z79.2 Long term (current) use of antibiotics

> Altabax Amikacin Amoxicillin Ampicillin Augmentin Avelox Azactam Azithromycin Bactrim Biaxin XL Cefazolin sodium Cefepime hydrochloride Cefprozil Ceftriaxone

Cefuroxime sodium Centany Cephalexin Cipro . Ciprofloxacin Clarithromycin

Cleocin Clindamycin Daptomycin Dificid Doxycycline E.E.S. Ertapenem

ERYC Erygel EryPed Ery-Tab Erythrocin Erythromycin Fetroja Flagyl

Gentamicin sulfate

Hiprex Invanz Isoniazid Klaron Lincocin Macrobid Macrodantin Mepron Merrem Metronidazole Minocin Monodox Monurol Mycobutin Nebupent Neosporin Nitrofurantoin Oracea

Penicillin-VK Pentam Pfizerpen Priftin Primaxin Rifadin Rimactane

Orbactiv

Septra Seromycin Silvadene Sivextro Solodyn

Streptomycin sulfate

Suprax Synercid Talicia Tazicef Teflaro Tetracycline Tobramycin Trimethoprim Tygacil Únasyn Vabomere Vancocin HCl Vancomycin HCI

Vibativ Vibramycin Voquezna Xacduro Xenleta Xifaxan Zerbaxa Zithromax Zvvox

Long term (current) use of hormonal contraceptives

Aranelle

Aviane-28 Beyaz Briellyn Camila Daysee Depo-Provera Depo-SubQ Provera Desogestrel/ethinyl estradiol Enpresse-28

Femhrt Gildagia Gildess 24 FE Junel Levonest Liletta Lo Loestrin Fe Loryna LoŚeasonique Low-Ogestrel-28 Mirena

Mono-Linyah Natazia Nexplanon NuvaRing Plan B One-Step Provera Seasonale

Seasonique Skyla Sprintec Tri-Lo-Estarylla Tri-Lo-Sprintec Tri-Sprintec Velivet Xulane Yasmin Yaz Zovia 1/50E-28

Z79.4 Long term (current) use

of insulin Admelog **Apidra** . Basaglar Fiasp Humalog Humulin R Lantus Levemir Novolin Novolog Soliqua Toujeo Solostar Tresiba

Xultophy 100/3.6 Long term (current) use Z79.51 of inhaled steroids

Advair

AirDuo RespiClick Alvesco **Arnuity Ellipta** Asmanex Breo Ellipta Dulera Flovent HFA Pulmicort Ovar Redihaler Symbicort Trelegy Ellipta

Z79.52 Long term (current) use of systemic steroids

Agamree Celestone Soluspan Colocort Cortef Cortenema Cortifoam Depo-Medrol

Hydrocortisone

. Dexamethasone Intensol Entocort EC

Kenalog-10 Kenalog-40 Locoid Medrol Methylprednisolone Orapred ODT PediaPred Prednisolone Prednison

Rayos Solu-Cortef Solu-Medrol

Z79.61 Long term (current) use of immunomodulator

Otezla **Pomalyst** Revlimid Thalomid

Z79.620 Long term (current) use of immunosuppressive

biologic Actemra Aimovia Beyfortus Briumvi Columvi Cosentyx Cyltezo **D**upixent Elrexfio Enbrel Entyvio Epkinly Humira Hyrimoz Imjudo

Logtorzi Monoclonal antibodies

Omvoh Prolia Remicade Rituxan Simulect Skyrizi Stelara Taltz Tremfya Xgeva


Keytruda

Z79.621 Long term (current) use of calcineurin inhibitor


Astagraf XL Cyclosporine Énvarsus XR Gengraf Lupkynis Neoral Prograf Protonic Restasis Sandimmune Tacrolimus

18 - Appendixes ICD-10-CM 2026 ICD-10-CM 2026 Illustrations

Internal Carotid and Vertebral Arteries and Branches



External Carotid Artery and Branches



ICD-10-CM 2026 Illustrations-21